Alpha-GPC (L-Alpha-Glycerylphosphorylcholine)
Highly bioavailable choline source that crosses the blood-brain barrier. Rapidly converted to choline and glycerophosphate. Supports acetylcholine synthesis and phosphatidylcholine membrane production. Peak plasma levels within 0.5-2 hours.
Projected serum levels — 300 mg, once daily
Maintenance schedule: 300 mg once daily (oral).
Modeled steady state after ~1 days: peak ≈ 221 mg, trough ≈ 18.4 mg body load. Population-based estimate over 15 days for a 300 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Cholinergic
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 6 h
- Common dose
- 300 mg
- Suggested maximum
- 1.2k mg/day
- Reference dose range
- 150–1.2k mg (single dose)
- Suggested cadence
- once daily
Research behind this entry
-
Activity of choline alphoscerate on adult-onset cognitive dysfunctions: a systematic review and meta-analysis
Systematic review and meta-analysis found that Alpha-GPC alone or combined with donepezil improved cognition, behavior, and functional outcomes in patients with cerebrovascular cognitive impairment.
-
Acute alpha-glycerylphosphorylcholine supplementation enhances cognitive performance in healthy men
Randomised double-blind crossover study in 20 healthy resistance-trained males showed both 315 mg and 630 mg Alpha-GPC significantly improved Stroop test performance acutely.
-
Absorption, tissue distribution and excretion of radiolabelled compounds in rats after administration of [14C]-L-alpha-glycerylphosphorylcholine
Radiolabelled pharmacokinetic study demonstrating widespread tissue distribution of Alpha-GPC metabolites including significant brain uptake, confirming its ability to deliver choline across the blood-brain barrier.
3 published studies referenced in the app, each with a plain-language summary.